Optiscan Imaging Begins In-Human Breast Cancer Clinical Study
MT Newswires Live
Jun 30
Optiscan Imaging (ASX:OIL) began its first in-human breast cancer clinical study at the Royal Melbourne Hospital to assess surgical margins in patients receiving treatment for breast cancer using its imaging devices, according to a Monday Australian bourse filing.
The 50-patient study will welcome patients for recruitment for in vivo clinical assessment of breast cancer margins following a lumpectomy procedure. It will use Optiscan's InVue precision surgery and InForm digital pathology imaging devices.
The study completed site initiation.
It will use the data for submissions to the US Food and Drug Administration.
The firm's shares jumped 10% on market close on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.